We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
UK experience of ofatumumab in recurrence of focal segmental glomerulosclerosis post-kidney transplant.
- Authors
Reynolds, Ben C.; Lamb, Angela; Jones, Caroline A.; Yadav, Pallavi; Tyerman, Kay S.; Geddes, Colin C.
- Abstract
Background: Steroid-resistant nephrotic syndrome (SRNS), commonly caused by focal segmental glomerulosclerosis (FSGS), is associated with progression to stage 5 chronic kidney disease, requirement for kidney replacement therapy and a risk of disease recurrence post-kidney transplantation. Ofatumumab (OFA) is a fully humanised monoclonal antibody to CD20, with similar mechanisms of action to rituximab (RTX). Methods: We report a case series of seven UK patients (five paediatric, two adult), all of whom developed FSGS recurrence after kidney transplantation and received OFA as part of their therapeutic intervention. All also received concomitant plasmapheresis. The 2-year outcome of these seven patients is reported, describing clinical course, kidney function and proteinuria. Results: Four patients (all paediatric) achieved complete urinary remission with minimal proteinuria 12 months post-treatment. Three of those four also had normal graft function. Two patients showed partial remission—brief improvement to non-nephrotic proteinuria (197 mg/mmol) in one patient, maintained improvement in kidney function (estimated glomerular filtration rate 76 ml/min/1.73 m2) in the other. One patient did not demonstrate any response. Conclusions: OFA may represent a useful addition to therapeutic options in the management of FSGS recurrence post-transplantation, including where RTX has shown no benefit. Concomitant plasmapheresis in all patients prevents any definitive conclusion that OFA was the beneficial intervention.
- Subjects
UNITED Kingdom; STEROID drugs; GLOMERULAR filtration rate; NEPHROTIC syndrome; KIDNEY transplantation; MONOCLONAL antibodies; DRUG resistance; IMMUNOSUPPRESSION; TREATMENT effectiveness; CASE studies; PLASMAPHERESIS; FOCAL segmental glomerulosclerosis
- Publication
Pediatric Nephrology, 2022, Vol 37, Issue 1, p199
- ISSN
0931-041X
- Publication type
Article
- DOI
10.1007/s00467-021-05248-9